Quince Q2 FY26 net loss widens to $75.5 million
QNCX•Program timeline
- LAM-001 Phase 2 BOS data is expected in Q1 2027.
- Phase 2b PH-ILD data is expected in Q1 2028, with a SAPH Phase 2 start planned for late 2026.
Quarterly loss, expenses and cash position
- Quince Therapeutics posted a GAAP net loss of $75.5 million, or $12.31 per share, for Q2 2026.
- R&D expense fell 16.67% to $5.5 million; the decline reflected lower eDSP program costs, partly offset by higher LAM-001 startup spending.
- G&A expense more than doubled to $16.6 million, driven by a $9.1 million non-cash stock-comp charge and higher professional fees.
- Cash and cash equivalents totaled $116 million at June 30, 2026, following $103.6 million in net upfront private placement proceeds.
